China channel feed – Endpoints News

China channel feed

Novartis’ oncology research chief in China jumps to upstart EpimAb in Shanghai

8 years ago

A week of UK deals exemplifies China’s growing role in global biotech investment

8 years ago

Billion-dollar biosim maker mulls $500M Hong Kong IPO

8 years ago

After EMA flop, Puma takes Nerlynx to China in new out-licensing deal

8 years ago

Fast-growing Shanghai Pharma to plant foot in San Diego, hunting deals in US and Europe

8 years ago

In a breakthrough, Chinese researchers clone monkeys hoping to provide better disease models

8 years ago

China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

8 years ago

AstraZeneca teams with China-owned fund to launch a new biopharma drug development company

8 years ago

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

8 years ago

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

A China biotech unicorn scores big with $150M-plus IPO on Nasdaq, stock rockets up

8 years ago

Top 5 biopharma trends: The long-awaited biopharma revolution in China has arrived — don’t lose out

8 years ago

As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D

8 years ago

Celgene-partnered Antengene preps new China deals as $21M round lands

8 years ago

With a big stake in hand, Samantha Du files for $115M IPO for Zai Lab

8 years ago

China biotech bags a $57M round as it races to complete R&D, manufacturing site

8 years ago

10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul

8 years ago

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

8 years ago

With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M

8 years ago

New Chinese VC leads $10M round for a Harvard spinout looking to industrialize platelet manufacturing

8 years ago

Nanjing Legend wows ASCO researchers with early data on a BCMA-targeted CAR-T contender

8 years ago

First page Previous page 25 26 272829 Next page Last page